

IN THE CLAIMS

Delete claims 155, 161, 167, 173-176, 183-186, 192-195 and 201-204.

Please amend claim 177 as follows:

177 (Amended). The therapeutic composition of claim 210 or 211, wherein said genetically-engineered monoclonal antibody is a single-chain antibody.

Please insert new claims 210-213 as follows:

210 (New). A therapeutic composition, comprising:  
a pharmaceutical formulation comprising

(1) a pharmaceutically acceptable carrier and

(2)(a) a genetically-engineered antibody that  
inhibits aggregation of beta-amyloid or maintains the  
solubility of soluble beta-amyloid, or

(b) a fragment of the genetically-engineered  
antibody of (a) that inhibits aggregation of beta-amyloid or  
maintains the solubility of soluble beta-amyloid,

wherein said genetically-engineered antibody is  
obtained from a monoclonal antibody that

(i) inhibits aggregation of beta-amyloid or  
maintains the solubility of soluble beta-amyloid and

(ii) is obtainable using residues 1-28 of beta-  
amyloid as an immunogen or recognizes an epitope within  
residues 1-28 of beta-amyloid.

211 (New). The therapeutic composition of claim  
210, wherein said genetically-engineered antibody of (2)(a)  
inhibits aggregation of human beta-amyloid or maintains the

solubility of soluble human beta-amyloid, or said fragment of  
(2) (b) inhibits aggregation of human beta-amyloid or maintains  
the solubility of soluble human beta-amyloid, and said  
genetically-engineered antibody of (2) (a) is obtained from a  
monoclonal antibody that inhibits aggregation of human beta-  
amyloid or maintains the solubility of soluble human beta-  
amyloid and said monoclonal antibody is obtainable using  
residues 1-28 of human beta-amyloid as an immunogen or  
recognizes an epitope within residues 1-28 of human beta-  
amyloid.

212 (New). A therapeutic composition, comprising:  
a pharmaceutical formulation comprising

(1) a pharmaceutically acceptable carrier and

(2) (a) a human monoclonal antibody that inhibits  
aggregation of beta-amyloid or maintains the solubility of  
soluble beta-amyloid, or

(b) a fragment of the human monoclonal antibody  
of (a) that inhibits aggregation of beta-amyloid or maintains  
the solubility of soluble beta-amyloid,

wherein said human monoclonal antibody is obtainable  
using residues 1-28 of beta-amyloid as an immunogen.

213 (New). The therapeutic composition of claim  
212, wherein said human monoclonal antibody of (2) (a) inhibits  
aggregation of human beta-amyloid or maintains the solubility  
of soluble human beta-amyloid, or said fragment of (2) (b)  
inhibits aggregation of human beta-amyloid or maintains the  
solubility of soluble human beta-amyloid, and wherein said

Appln. No. 09/441,140  
Amendment dated August 2, 2006  
Reply to Office action of June 2, 2006

human monoclonal antibody of (a) is obtainable using residues  
1-28 of human beta-amyloid as an immunogen.